End-stage Renal Disease Costs for Patients New to Hemodialysis in Italy: The FARO-2 Study.
Roggeri DP, Roggeri A, Brancaccio D, Mazzaferro S, Messa P, Paoletti E, Possidoni A, Costanzo AM, di Luzio Paparatti U, Cozzolino M and On behalf of the FARO-2 Study Group. British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol. 12, Issue. 5
Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study.
Roggeri DP, Cozzolino M, Mazzaferro S, Brancaccio D, Paoletti E, Roggeri A, Costanzo AM, di Luzio Paparatti U, Festa V, Messa P. Int J Nephrol Renovasc Dis. 2014 Dec 16;8:1-6. doi: 10.2147/IJNRD.S72011. eCollection 2015.
Outcomes, health costs and use of antiplatelet agents in 7082 patients admitted for an Acute Coronary Syndrome occurring in a large community setting.
AP Maggioni, E Rossi, E Cinconze, DP Roggeri, A Roggeri, A Fabbri and M De Rosa, on the behalf of the ARNO Cardiovascular Observatory. Cardiovascular Drugs and Therapy , March 2013 DOI:10.1007/s10557-013-6455-z
Comparison of Fluvastatin + Fenofibrate combination therapy and Fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 Mellitus diabetes, and coronary heart disease: a twelve month, randomized, double-blind, controlled trial.
G. Derosa, A.F.G. Cicero, G. Bertone, M. Piccinini, L. Ciccarelli, D.P. Roggeri, R. Fogari. Clinical Therapeutics 26:8, 2004. DOI: 10.1016/j.clinthera.2004.10.008
Consumption of resources and costs for the diagnosis and treatment of gastrointestinal adverse events due to the use of Non Steroidal Anti-inflammatory Drugs (FANS): retrospective study conducted among general practitioners.
S. Chiroli, D. Roggeri. Pharmacoeconomics Italian Research Articles 3(2): 61-70,2001.